Agenus (AGEN) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
Agenus Provides R&D Update & Second Quarter Financial Report
August 6, 2020 7:30 AM EDTLEXINGTON, Mass., Aug. 6, 2020 /PRNewswire/ --Â Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided an R&D and business update and reported financial results for the second quarter of 2020.
... More


